Quent Capital LLC Sells 3,232 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Quent Capital LLC reduced its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 76.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 983 shares of the biotechnology company’s stock after selling 3,232 shares during the quarter. Quent Capital LLC’s holdings in United Therapeutics were worth $347,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in UTHR. SG Americas Securities LLC raised its holdings in shares of United Therapeutics by 66.1% in the 3rd quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company’s stock valued at $535,000 after purchasing an additional 594 shares during the period. CWM LLC increased its position in United Therapeutics by 108.3% during the third quarter. CWM LLC now owns 4,006 shares of the biotechnology company’s stock worth $1,436,000 after buying an additional 2,083 shares during the last quarter. Ritholtz Wealth Management raised its stake in United Therapeutics by 14.3% in the third quarter. Ritholtz Wealth Management now owns 839 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 105 shares during the period. CHICAGO TRUST Co NA acquired a new stake in shares of United Therapeutics in the third quarter valued at approximately $204,000. Finally, Creative Planning boosted its stake in shares of United Therapeutics by 8.9% during the 3rd quarter. Creative Planning now owns 3,935 shares of the biotechnology company’s stock worth $1,410,000 after acquiring an additional 322 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on UTHR. LADENBURG THALM/SH SH increased their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. TD Cowen increased their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. HC Wainwright upped their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $353.31 on Wednesday. United Therapeutics Co. has a fifty-two week low of $210.64 and a fifty-two week high of $417.82. The company has a market cap of $15.78 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57. The stock has a fifty day moving average price of $362.06 and a 200-day moving average price of $358.24.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 121,864 shares of company stock valued at $44,516,965 over the last quarter. 11.90% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.